NO2016023I2 - Glycerolfenylbutyrat - Google Patents

Glycerolfenylbutyrat

Info

Publication number
NO2016023I2
NO2016023I2 NO2016023C NO2016023C NO2016023I2 NO 2016023 I2 NO2016023 I2 NO 2016023I2 NO 2016023 C NO2016023 C NO 2016023C NO 2016023 C NO2016023 C NO 2016023C NO 2016023 I2 NO2016023 I2 NO 2016023I2
Authority
NO
Norway
Prior art keywords
glycerolfenylbutyrat
Prior art date
Application number
NO2016023C
Other languages
English (en)
Other versions
NO2016023I1 (no
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41255339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2016023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of NO2016023I1 publication Critical patent/NO2016023I1/no
Publication of NO2016023I2 publication Critical patent/NO2016023I2/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2016023C 2008-04-29 2016-12-14 Glycerolfenylbutyrat NO2016023I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4883008P 2008-04-29 2008-04-29
US9323408P 2008-08-29 2008-08-29

Publications (2)

Publication Number Publication Date
NO2016023I1 NO2016023I1 (no) 2016-12-14
NO2016023I2 true NO2016023I2 (no) 2016-12-27

Family

ID=41255339

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2016023C NO2016023I2 (no) 2008-04-29 2016-12-14 Glycerolfenylbutyrat

Country Status (12)

Country Link
US (2) US8642012B2 (no)
EP (2) EP2330892B1 (no)
CA (1) CA2735218A1 (no)
CY (3) CY1118543T1 (no)
DK (1) DK2330892T3 (no)
GB (1) GB2470310A (no)
HU (1) HUS1600057I1 (no)
LT (1) LTC2330892I2 (no)
NL (1) NL300854I2 (no)
NO (1) NO2016023I2 (no)
PL (1) PL3133396T3 (no)
WO (1) WO2009134460A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
ES2629859T3 (es) * 2011-09-30 2017-08-16 Horizon Therapeutics, Llc Fármacos para eliminar nitrógeno para su uso en un procedimiento para tratar un trastorno de retención de nitrógeno
CN104540507A (zh) 2012-04-20 2015-04-22 海波龙治疗公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
RS59429B1 (sr) 2013-10-14 2019-11-29 Immedica Pharma Ab Postupci tretmana poremećaja ciklusa uree
CA3197154A1 (en) 2013-11-14 2015-05-21 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses thereof
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
EP3368088B1 (en) 2015-10-29 2023-06-07 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
WO2018170234A1 (en) 2017-03-15 2018-09-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
AU2018272294B2 (en) * 2017-05-24 2024-05-23 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
BR112019028097A2 (pt) 2017-06-28 2020-07-28 Baylor College Of Medicine terapia combinada para tratar distúrbios do ciclo de ureia
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
DE69612755T2 (de) * 1995-02-07 2001-08-23 Brusilow Entpr Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
DE19805854C1 (de) * 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
ES2537974T3 (es) * 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
CA2711807A1 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
WO2010025303A1 (en) 2008-08-29 2010-03-04 Hyperion Therapeutics Dosing and monitoring patients on nitrogen-scavenging drugs

Also Published As

Publication number Publication date
US20100008859A1 (en) 2010-01-14
GB201013468D0 (en) 2010-09-22
LTC2330892I2 (lt) 2018-06-11
NL300854I2 (no) 2017-02-02
EP3133396B1 (en) 2018-09-05
EP2330892B1 (en) 2016-06-29
US8642012B2 (en) 2014-02-04
HUS1600057I1 (hu) 2017-01-30
CY1121288T1 (el) 2020-05-29
PL3133396T3 (pl) 2019-03-29
EP2330892A1 (en) 2011-06-15
CY2016053I1 (el) 2017-06-28
CY1118543T1 (el) 2017-06-28
EP3133396A1 (en) 2017-02-22
GB2470310A (en) 2010-11-17
EP2330892A4 (en) 2012-01-11
US20140256807A1 (en) 2014-09-11
DK2330892T3 (en) 2016-08-22
LTPA2016041I1 (lt) 2017-01-10
CY2016053I2 (el) 2017-06-28
NO2016023I1 (no) 2016-12-14
CA2735218A1 (en) 2009-11-05
WO2009134460A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
NO2016023I2 (no) Glycerolfenylbutyrat
DK2370462T3 (da) Glucagon-analoger
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2342454T3 (da) Vindkraftanlæg
DK2379557T3 (da) Aminopyrazol-forbindelse
DE602008003970D1 (de) Strahlstromkalibriersystem
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0907522A2 (pt) biarlamidas
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909637A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
DK2344933T3 (da) Uretui
DE602009000862D1 (de) Gehwagenbremse
AT507449A3 (de) Dämmstoffbefestiger
DE602009001190D1 (de) Gleichstromumrichtervorrichtung